Literature DB >> 8683727

Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue.

R A Morton1, J J Watkins, G S Bova, M M Wales, S B Baylin, W B Isaacs.   

Abstract

PURPOSE: Under normal conditions genomic CpG islands are not methylated. Hypermethylation of a CpG island in the 5' regulatory region of a gene has the capacity to silence gene transcription. Recently, hypermethylation of a CpG island at D17S5 on chromosome 17P13.3 has been shown to be a frequent tumor-specific event. When it has been observed, hypermethylation of D17S5 occurs solely in neoplastic tissues. Consequently, it has been hypothesized that hypermethylation of D17S5 may be an important carcinogenic event in the organs in which it occurs (colon, kidney, and brain). In this study we examine D17S5 hypermethylation in DNA from the prostate, a gland which is unique in that it undergoes hyperplastic or neoplastic growth or both in virtually all aging men.
MATERIALS AND METHODS: The methylation sensitive restriction enzyme Notl, a cDNA probe specific for the D17S5 locus, and Southern blotting were used to assay for hypermethylation of D17S5 in DNA derived from normal, benign hyperplastic and malignant prostate tissues.
RESULTS: We find that methylation of Notl restriction sites at D17S5 is a very common occurrence in prostate cancers (25 of 26 cases examined). Surprisingly, we found that methylation of these sites at D17S5 also occurred in histologically normal prostate and benign hyperplastic (BPH) tissue from glands which both did and did not contain cancer. In contrast, seminal vesicle, an androgen-dependent male sex accessory tissue that rarely undergoes pathological overgrowth, was devoid of hypermethylation at this locus. CONCLUSIONS. These data demonstrate that hypermethylation of D17S5 is a tissue-specific event in prostate DNA, and we hypothesize that methylation of this and/or related loci may play a role in the extreme predilection of this gland to neoplastic growth.

Entities:  

Mesh:

Year:  1996        PMID: 8683727     DOI: 10.1097/00005392-199608000-00073

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

Review 1.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

Review 2.  SIRT1 and p53, effect on cancer, senescence and beyond.

Authors:  Jingjie Yi; Jianyuan Luo
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 3.  Molecular genetics of prostate cancer: clinical applications.

Authors:  R A Morton; W B Isaacs
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

4.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

5.  Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression.

Authors:  Jianghua Zheng; Dan Xiong; Xueqing Sun; Jinglong Wang; Mingang Hao; Tao Ding; Gang Xiao; Xiumin Wang; Yan Mao; Yuejie Fu; Kunwei Shen; Jianhua Wang
Journal:  Cancer Microenviron       Date:  2012-04-13

6.  Small extracellular vesicle-associated miR-6068 promotes aggressive phenotypes of prostate cancer through miR-6068/HIC2/SIRT1 axis.

Authors:  Mohamed S A Gaballah; Hamdy E A Ali; Zeinab A Hassan; Shahenda Mahgoub; Hamid I Ali; Johng S Rhim; Mourad Zerfaoui; Khalid A El Sayed; David Stephen; Paul W Sylvester; Zakaria Y Abd Elmageed
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

7.  P53 induction accompanying G2/M arrest upon knockdown of tumor suppressor HIC1 in U87MG glioma cells.

Authors:  Sanjay Kumar
Journal:  Mol Cell Biochem       Date:  2014-07-04       Impact factor: 3.396

8.  Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1).

Authors:  Capucine Van Rechem; Brian R Rood; Majid Touka; Sébastien Pinte; Mathias Jenal; Cateline Guérardel; Keri Ramsey; Didier Monté; Agnès Bégue; Mario P Tschan; Dietrich A Stephan; Dominique Leprince
Journal:  J Biol Chem       Date:  2009-06-12       Impact factor: 5.157

9.  Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region.

Authors:  Carola Hedberg Oldfors; Diego Garcia Dios; Anna Linder; Kittichate Visuttijai; Emma Samuelson; Sandra Karlsson; Staffan Nilsson; Afrouz Behboudi
Journal:  BMC Genet       Date:  2015-07-14       Impact factor: 2.797

10.  HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy.

Authors:  Lucie Janeckova; Michal Kolar; Jiri Svec; Lucie Lanikova; Vendula Pospichalova; Nikol Baloghova; Martina Vojtechova; Eva Sloncova; Hynek Strnad; Vladimir Korinek
Journal:  Transl Oncol       Date:  2016-03-04       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.